Tucatinib 150mg Tablets – Advanced HER2-Targeted Cancer Therapy
Tucatinib 150mg Tablets are a targeted anti-cancer medication used primarily in combination therapy for the treatment of HER2-positive metastatic breast cancer and certain cases of HER2-positive metastatic colorectal cancer. Tucatinib is a highly selective HER2 tyrosine kinase inhibitor that helps slow cancer growth while minimizing effects on healthy cells. It is approved for use in combination with trastuzumab and, depending on the indication, capecitabine.
Cordium Pharmaceuticals Pvt. Ltd. is a trusted pharmaceutical manufacturer and global exporter committed to delivering high-quality oncology medicines to healthcare providers, distributors, hospitals, and pharmacies across the USA, UAE, UK, South Africa, Singapore, Australia, Canada, and Germany.
Product Overview
Product Name: Tucatinib Tablets
Strength: 150 mg
Dosage Form: Oral Tablets
Therapeutic Category: Oncology / Targeted Therapy
Manufacturer: Cordium Pharmaceuticals Pvt. Ltd.
Prescription Status: Prescription Only Medicine
Medical Uses of Tucatinib 150mg Tablets
Tucatinib is prescribed for adults with:
HER2-positive unresectable or metastatic breast cancer
Breast cancer with brain metastases
HER2-positive, RAS wild-type metastatic colorectal cancer (in approved treatment settings)
The medicine is typically administered alongside other anti-cancer agents according to an oncologist's treatment plan.
How Tucatinib Works
Tucatinib selectively blocks the HER2 receptor, a protein responsible for promoting cancer cell growth in HER2-positive tumors. By inhibiting HER2 signaling, Tucatinib helps:
Slow tumor progression
Reduce cancer cell multiplication
Improve treatment response when combined with trastuzumab and capecitabine (where indicated)
Its selectivity for HER2 may reduce inhibition of EGFR compared with less selective kinase inhibitors.
Global Supply by Cordium Pharmaceuticals
Cordium Pharmaceuticals supplies Tucatinib 150mg Tablets to international markets including:
🇺🇸 USA
🇦🇪 UAE
🇬🇧 United Kingdom
🇿🇦 South Africa
🇸🇬 Singapore
🇦🇺 Australia
🇨🇦 Canada
🇩🇪 Germany
The company serves:
Pharmaceutical Importers
Oncology Hospitals
Government Healthcare Programs
Cancer Clinics
Medical Distributors
Institutional Buyers
Benefits of Tucatinib Therapy
Targeted HER2 inhibition
Oral tablet formulation
Widely used in combination therapy
Demonstrated activity in HER2-positive metastatic disease, including patients with brain metastases in approved settings
Supports personalized oncology treatment plans
Possible Side Effects
Like all prescription medicines, Tucatinib may cause side effects, including:
Diarrhea
Fatigue
Nausea
Vomiting
Decreased appetite
Elevated liver enzymes
Hand-foot syndrome (when used with capecitabine)
Patients should use Tucatinib only under the supervision of a qualified oncologist and follow all recommended monitoring.
Why Choose Cordium Pharmaceuticals Pvt. Ltd.?
Cordium Pharmaceuticals is recognized for its commitment to quality, affordability, and global pharmaceutical supply.
Key Advantages
High-quality oncology product portfolio
International export capabilities
Competitive pricing
Reliable global logistics
Consistent manufacturing standards
Professional customer support
Timely deliveries
Focus on long-term distributor partnerships
Whether you are a wholesaler, distributor, hospital, or healthcare procurement organization, Cordium Pharmaceuticals aims to provide dependable pharmaceutical supply solutions for international markets.
Frequently Asked Questions (FAQs)
1. What is Tucatinib 150mg used for?
Tucatinib is used in combination with other medicines for treating HER2-positive metastatic breast cancer and certain HER2-positive metastatic colorectal cancers in appropriate patients.
2. Is Tucatinib chemotherapy?
No. Tucatinib is a targeted therapy (HER2 tyrosine kinase inhibitor), not traditional chemotherapy.
3. Can Tucatinib be taken alone?
Treatment regimens generally combine Tucatinib with trastuzumab and, depending on the indication, capecitabine. Patients should follow their oncologist's prescribed regimen.
4. Which countries does Cordium Pharmaceuticals supply?
Cordium Pharmaceuticals supplies pharmaceutical products to customers in the USA, UAE, UK, South Africa, Singapore, Australia, Canada, Germany, and many other international markets.
5. Is Tucatinib available in 150mg strength?
Yes. Tucatinib is available as 150 mg tablets, which are commonly used as part of the recommended dosing regimen.
6. Is a prescription required?
Yes. Tucatinib is a prescription-only oncology medicine and should be used only under medical supervision.
7. Can distributors source Tucatinib from Cordium Pharmaceuticals?
Yes. Cordium Pharmaceuticals works with qualified distributors, hospitals, pharmacies, and institutional buyers seeking reliable oncology medicine supply.
Tucatinib 150mg Tablets are a targeted anti-cancer medication used primarily in combination therapy for the treatment of HER2-positive metastatic breast cancer and certain cases of HER2-positive metastatic colorectal cancer. Tucatinib is a highly selective HER2 tyrosine kinase inhibitor that helps slow cancer growth while minimizing effects on healthy cells. It is approved for use in combination with trastuzumab and, depending on the indication, capecitabine.
Cordium Pharmaceuticals Pvt. Ltd. is a trusted pharmaceutical manufacturer and global exporter committed to delivering high-quality oncology medicines to healthcare providers, distributors, hospitals, and pharmacies across the USA, UAE, UK, South Africa, Singapore, Australia, Canada, and Germany.
Product Overview
Product Name: Tucatinib Tablets
Strength: 150 mg
Dosage Form: Oral Tablets
Therapeutic Category: Oncology / Targeted Therapy
Manufacturer: Cordium Pharmaceuticals Pvt. Ltd.
Prescription Status: Prescription Only Medicine
Medical Uses of Tucatinib 150mg Tablets
Tucatinib is prescribed for adults with:
HER2-positive unresectable or metastatic breast cancer
Breast cancer with brain metastases
HER2-positive, RAS wild-type metastatic colorectal cancer (in approved treatment settings)
The medicine is typically administered alongside other anti-cancer agents according to an oncologist's treatment plan.
How Tucatinib Works
Tucatinib selectively blocks the HER2 receptor, a protein responsible for promoting cancer cell growth in HER2-positive tumors. By inhibiting HER2 signaling, Tucatinib helps:
Slow tumor progression
Reduce cancer cell multiplication
Improve treatment response when combined with trastuzumab and capecitabine (where indicated)
Its selectivity for HER2 may reduce inhibition of EGFR compared with less selective kinase inhibitors.
Global Supply by Cordium Pharmaceuticals
Cordium Pharmaceuticals supplies Tucatinib 150mg Tablets to international markets including:
🇺🇸 USA
🇦🇪 UAE
🇬🇧 United Kingdom
🇿🇦 South Africa
🇸🇬 Singapore
🇦🇺 Australia
🇨🇦 Canada
🇩🇪 Germany
The company serves:
Pharmaceutical Importers
Oncology Hospitals
Government Healthcare Programs
Cancer Clinics
Medical Distributors
Institutional Buyers
Benefits of Tucatinib Therapy
Targeted HER2 inhibition
Oral tablet formulation
Widely used in combination therapy
Demonstrated activity in HER2-positive metastatic disease, including patients with brain metastases in approved settings
Supports personalized oncology treatment plans
Possible Side Effects
Like all prescription medicines, Tucatinib may cause side effects, including:
Diarrhea
Fatigue
Nausea
Vomiting
Decreased appetite
Elevated liver enzymes
Hand-foot syndrome (when used with capecitabine)
Patients should use Tucatinib only under the supervision of a qualified oncologist and follow all recommended monitoring.
Why Choose Cordium Pharmaceuticals Pvt. Ltd.?
Cordium Pharmaceuticals is recognized for its commitment to quality, affordability, and global pharmaceutical supply.
Key Advantages
High-quality oncology product portfolio
International export capabilities
Competitive pricing
Reliable global logistics
Consistent manufacturing standards
Professional customer support
Timely deliveries
Focus on long-term distributor partnerships
Whether you are a wholesaler, distributor, hospital, or healthcare procurement organization, Cordium Pharmaceuticals aims to provide dependable pharmaceutical supply solutions for international markets.
Frequently Asked Questions (FAQs)
1. What is Tucatinib 150mg used for?
Tucatinib is used in combination with other medicines for treating HER2-positive metastatic breast cancer and certain HER2-positive metastatic colorectal cancers in appropriate patients.
2. Is Tucatinib chemotherapy?
No. Tucatinib is a targeted therapy (HER2 tyrosine kinase inhibitor), not traditional chemotherapy.
3. Can Tucatinib be taken alone?
Treatment regimens generally combine Tucatinib with trastuzumab and, depending on the indication, capecitabine. Patients should follow their oncologist's prescribed regimen.
4. Which countries does Cordium Pharmaceuticals supply?
Cordium Pharmaceuticals supplies pharmaceutical products to customers in the USA, UAE, UK, South Africa, Singapore, Australia, Canada, Germany, and many other international markets.
5. Is Tucatinib available in 150mg strength?
Yes. Tucatinib is available as 150 mg tablets, which are commonly used as part of the recommended dosing regimen.
6. Is a prescription required?
Yes. Tucatinib is a prescription-only oncology medicine and should be used only under medical supervision.
7. Can distributors source Tucatinib from Cordium Pharmaceuticals?
Yes. Cordium Pharmaceuticals works with qualified distributors, hospitals, pharmacies, and institutional buyers seeking reliable oncology medicine supply.
Keywords
